Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent mycobacterium tuberculosis infection

Morbidity and Mortality Weekly Report

Volumn 60, Issue 48, 2011, Pages 1650-1653

  Jereb, John A ^a   Goldberg, Stefan V ^a   Powell, Krista ^a   Villarino, M Elsa ^a   Lobue, Philip ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DERIVATIVE; ISONIAZID; RIFAMPICIN; RIFAPENTINE; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; CHILD; DIRECTLY OBSERVED THERAPY; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG CONTRAINDICATION; EVIDENCE BASED MEDICINE; HUMAN; LATENT TUBERCULOSIS; PRACTICE GUIDELINE; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADULT; ANTITUBERCULAR AGENTS; CHILD; CHILD, PRESCHOOL; DIRECTLY OBSERVED THERAPY; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HUMANS; ISONIAZID; LATENT TUBERCULOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RIFAMPIN;

EID: 83155184045     PISSN: 01492195     EISSN: 1545861X     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. American Thoracic Society, CDC, Infectious Diseases Society of America. Controlling tuberculosis in the United States. Am J Respir Crit Care Med 2005;172:1169-227.
2. CDC. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR 2000;49(No. RR-6).
3. Schechter M, Zajdenverg R, Falco G, et al. Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts. Am J Respir Crit Care Med 2006;173:922-6.
4. Martinson NA, Barnes GL, Moulton LH, et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med 2011;365:11-20.
5. Sterling TR, Villarino ME, Borisov AS, et al. Three months of once-weekly rifapentine and isoniazid for M. tuberculosis infection. N Engl J Med 2011;365:2155-66.
6. Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006;174:935-52.
7. CDC. Severe isoniazid-associated liver injuries among persons being treated for latent tuberculosis infection-United States, 2004-2008. MMWR 2010;59:224-9.
8. CDC. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection-United States, 2003. MMWR 2003;52:735-9.
9. Girling DJ. Adverse effects of antituberculosis drugs. Drugs 1982;23:56-74.
10. Benator D, Bhattacharya M, Bozeman L, et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 2002;360:528-34.